Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Vaxart Q3 2026 Results: Net Loss of $17.7M, Loss Widens

This document outlines Vaxart, Inc.'s Director Resignation Policy, requiring directors in uncontested elections to tender their resignation if they receive a 'Majority Withheld Vote.' The Nominating and Governance Committee and the Board must evaluate such resignations based on factors like director qualifications and regulatory compliance within 90 days.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue10.672.4
Profit before tax-17.4-8.1
Net income-17.7-8.1
EPS (diluted, $ a share)$-0.07$-0.04

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-85.3%
Operating margin-162.7%
Source

10-Q filed with the SEC, OTC: VXRT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Vaxart, Inc.: key numbers

Share price
$0.3600Close, Nov 16
Market cap
$87.7M
Shares outstanding
243.7MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Vaxart, Inc.

All →
4:17 PM ET 8-K
Financial Results

Vaxart Financial Results

Vaxart reported third quarter 2026 financial results and provided a business update, highlighting $65.5 million in cash and a runway into Q2 2027. The company expects topline data from its Phase 2b COVID-19 trial, involving approximately 5,400 participants, by mid-year 2027. Additionally, Vaxart expanded its norovirus vaccine IP with a new European patent and appointed Retired Vice Admiral Raquel C. Bono to its Board of Directors.

“During the third quarter, the Vaxart team worked diligently to advance our Phase 2b COVID-19 trial. The release of the topline efficacy and safety data from the main cohort remains a top priority, and we continue to actively work toward completion of analytical testing and disclosure of the trial results, in collaboration with our partner BARDA.”

Steven Lo, Chief Executive Officer of Vaxart
4:07 PM ET 8-K
Leadership Change

Vaxart Leadership Change

Vaxart, Inc. appointed Raquel C. Bono, M.D., a retired U.S. Navy Vice Admiral and former Director of the Defense Health Agency, to its Board of Directors effective October 16, 2026. Dr. Bono will serve as Chair of the Stockholder Engagement Committee and was appointed pursuant to a cooperation agreement entered into with a group of stockholders in July 2026.

Counterparty
Raquel C. Bono
4:06 PM ET 8-K
Executive Compensation

Vaxart Executive Compensation

Vaxart's Board of Directors approved a new Director Stock Ownership Policy requiring non-employee directors to hold stock valued at two times their annual cash retainer. The Board also adopted a Director Resignation Policy requiring directors to tender their resignation if they receive more 'withhold' than 'for' votes in an uncontested election.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.